Evaluation of potential cytotoxic and apoptotic effects of bioymifi on human multiple myeloma cell lines

Purpose: To investigate the cytotoxic and apoptotic activities of bioymifi (DR5 agonist) on bortezomibsensitive and bortezomib-resistant cells. Methods: The cytotoxic activities of bioymifi against bortezomib-sensitive (U266) and bortezomib-resistant (U266/BR) cells were evaluated using XTT cell viability test. The cells were exposed to increasing concentrations of bioymifi for 24 h. Cell cycle analysis was performed while apoptosis was examined by flow cytometry. Results: Bioymifi showed significant cytotoxic effects on 0266 and U266/BR in a concentration-dependent manner (p < 0.05). The IC50 values of bioymifi in U266 and U266/BR cells were 10.4 and 20.9 mu M, respectively. Moreover, when compared to the untreated cells, bioymifi treatment at IC50 concentrations considerably increased the percentage of apoptotic cells. Bioymifi treatment also caused cell cycle arrest at the G2/M phase in both cell types. Conclusion: The results show that bioymifi is a promising candidate for multiple myeloma treatment. However, further studies are required to evaluate the clinical anticancer activity of this agent.